Almaject Patent-Cliff Exposure & CMS Drug Spending Portfolio

Almaject (US): 2 reconciled FDA prescription therapies, $231.3M 2024 CMS Part D & Medicaid spend, and $3,798 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$231.3M
2024 Medicare Part D Spend$212.6M
2024 Medicaid Spend$18.7M
California HCAI SB 17 FilingsSpecialty launch notice ($3,798 intro WAC)